Ovid Therapeutics Inc. (OVID) Dividend History

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for rare neurological disorders. Founded to address unmet medical needs, the company specializes in leveraging its expertise in neuroscience to bring innovative therapies to patients with conditions such as rare epilepsies and other central nervous system disorders.

441 Ninth Avenue, 14th Floor, New York, NY, 10001
Phone: 212-776-4381
Website: https://www.ovidrx.com

Dividend History

Ovid Therapeutics Inc. currently does not pay dividends

Company News

  • Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.

    GlobeNewswire Inc.
  • Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

    Seeking Alpha
  • Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.

    Zacks Investment Research
    Featured Companies: AMGN MRNA ZNTL
  • Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 2 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.38, along with a high estimate of $9.00 and a low estimate of $3.50. This upward trend is evident, with the current average reflecting a 84.5% increase from the previous average price target of $4.00. Breaking Down Analyst Ratings: A Detailed Examination In examining recent analyst actions, we gain insights into how financial experts perceive Ovid Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yigal Nochomovitz Citigroup Lowers Neutral $3.50 $4.00 Kalpit Patel B. Riley Securities Announces Buy $9.00 - Raghuram Selvaraju HC Wainwright & Co. Announces Buy $9.00 - Laura Chico Wedbush Announces Outperform $8.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ovid Therapeutics. ...Full story available on Benzinga.com

    Benzinga
Page data last updated 07/23/2025 09:39:40 UTC